VRC 606: A Phase 1, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs VRC 01LS (Primary) ; VRC 01LS (Primary) ; VRC 01; VRC 01
- Indications HIV infections
- Focus Adverse reactions
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2017 Planned End Date changed from 31 Aug 2017 to 31 Aug 2018.
- 06 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Aug 2018.